These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35200425)

  • 21. Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
    Galili U
    Med Res Arch; 2021 Jul; 9(7):. PubMed ID: 34853815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
    Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
    Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals.
    Li J; Chen W; Chen M; Bai S; Yuan Q; Wu J
    Hum Vaccin Immunother; 2021 Oct; 17(10):3310-3313. PubMed ID: 34348570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.
    Abdi Ghavidel A; Rojhannezhad M; Kazemi B; Bandehpour M
    Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):647-671. PubMed ID: 34920649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
    Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
    Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3.
    Fan YJ; Chan KH; Hung IF
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putative Role of Vitamin D for COVID-19 Vaccination.
    Chiu SK; Tsai KW; Wu CC; Zheng CM; Yang CH; Hu WC; Hou YC; Lu KC; Chao YC
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.
    Zhang R; Liu D; Leung KY; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?
    Alhinai ZA; Elsidig N
    Int J Infect Dis; 2021 Sep; 110():258-260. PubMed ID: 34157386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.
    Baldo A; Leunda A; Willemarck N; Pauwels K
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34063733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learned from COVID-19 pandemic: Vaccine platform is a key player.
    Hossaini Alhashemi S; Ahmadi F; Dehshahri A
    Process Biochem; 2023 Jan; 124():269-279. PubMed ID: 36514356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvants for COVID-19 Vaccines.
    Castrodeza-Sanz J; Sanz-Muñoz I; Eiros JM
    Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37243006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA.
    Rezaei M; Nazari M
    Avicenna J Med Biotechnol; 2022; 14(1):30-36. PubMed ID: 35509358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.
    Zhao L; Fu L; He Y; Li H; Song Y; Liu S
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Older adults: panoramic view on the COVID-19 vaccination.
    Andryukov BG; Besednova NN
    AIMS Public Health; 2021; 8(3):388-415. PubMed ID: 34395690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A brief review on DNA vaccines in the era of COVID-19.
    Shafaati M; Saidijam M; Soleimani M; Hazrati F; Mirzaei R; Amirheidari B; Tanzadehpanah H; Karampoor S; Kazemi S; Yavari B; Mahaki H; Safaei M; Rahbarizadeh F; Samadi P; Ahmadyousefi Y
    Future Virol; 2021 Nov; ():. PubMed ID: 34858516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.